About us
Translational Pharmaceutics®
Quotient Sciences first brought meaningful innovation to the pharmaceutical industry in 2008 with Translational Pharmaceutics® – a unique delivery platform that shortens development times by more than 12 months.
By integrating drug substance, drug product, and clinical testing activities, Translational Pharmaceutics® accelerates molecules through development. This saves time and money in reaching key milestones as quickly and efficiently as possible, ensuring better decision making and more streamlined outsourcing.
- Reducing the time from candidate development to first in human (FIH)
- Accelerating molecules from FIH to proof of concept (POC)
- Selecting and optimizing clinical formulations
- Accelerating products through to commercial manufacture
Our expertise in understanding dependencies between drug substance properties, formulation design, and clinical outcomes enables us to enhance development efficiency.
By having both drug substance and drug product manufacturing activities under one organization, we can now deliver integrated chemistry, manufacturing, and controls (CMC) development activities for both pre-clinical and clinical studies in parallel, simplifying the supply chain and shortening the time from candidate selection to clinic by a further 2–4 months.
Translational Pharmaceutics® has now been used by pharmaceutical and biotech companies on over 500 drug programs. The financial benefits and time savings were quantified in a publication by the Tufts Center for the Study of Drug Development.
Integrating drug substance & drug product for accelerated development of programs
The seamless coordination between drug substance and drug product manufacturing results in a more efficient and accelerated development plan. Integrating all activities under a single organization, and removing silos, encourages close relationships between multidisciplinary experts and creates a more agile approach to pharmaceutical development. Learn how a fully integrated program can speed up the transition from candidate selection to POC and shorten the pathway to clinical drug development.
What Our Clients Say
"Our small biotech company worked with Quotient Sciences on developing a complex formulation and validating the different iterations of the formulation in PK clinical studies using the Translational Pharmaceutics® approach. The project was successful, and we were generally impressed by the skillsets, professionalism, and courtesy of Quotient Sciences' scientists and other subject experts. We have also chosen to work with Quotient Sciences on two subsequent projects."
– Evecxia
Translational Pharmaceutics®
- A faster approach to drug development and accelerated time to market
- Timeline acceleration of >12 months
- Significant reduction in R&D spend
- Better decision making
- Greater likelihood of success
- Simplified supply chain
Read our Translational Pharmaceutics® blog
"Does Partnering with a Fully Integrated Services Provider Really Improve Your Molecule’s Chances of Clinical and Commercial Success?"
In this latest blog written by Quotient Sciences' Chief Scientific Officer, Dr Peter Scholes, he talks about the complexities and importance in selecting the right outsourcing partner for your drug development program. He also discusses how the climate of the pharmaceutical industry today can be challenging for drug developers to manage multiple vendors, projects can be slow to start, disconnects can lead to delayed timelines, and it can be extremely costly, which points to a need for a simplified outsourcing model.
-
Scientific PostersAAPS 2019 Poster - Rapid Transition of a Novel Celecoxib Formulation from a Fit-for-Phase Presentation to a Commercializable Product Using an Innovative Integrated Drug Development and Clinical Testing PlatformPresented at AAPS 2019: An integrated CMC and clinical development program successfully identified a commercializable formulation of DRGT-46 meeting required taste and PK attributes as per the Target Product Profile. Real time, adaptive GMP ensured formulation development decisions were taken based on human clinical data.
-
WebinarTufts CSDD Study Assessing the Financial Benefits of Translational Pharmaceutics®: A Platform for Accelerating Product DevelopmentThis webinar summarizes the key findings of the recent Tufts CSDD research into Translational Pharmaceutics, the innovative approach to drug development. Access our on-demand webinar now.
-
Case StudiesDruggability TechnologiesDruggability Technologies (DRGT) is developing DRGT-46 as a novel therapy for pain. Gabor Heltovics, former CEO of DRGT, explains how Quotient Sciences enabled the rapid development, clinical assessment and commercial readiness of its DRGT-46 product using integrated services across Quotient Sciences' network of harmonized development and manufacturing sites in the UK and US.
-
Info SheetTranslational Pharmaceutics® Fact SheetQuotient Sciences helps you achieve your goals by enabling precise formulation development, streamlined manufacturing, quick pivot to clinical data and a significantly faster transition through drug development.